What are the advancements driving CGT drug development?
In this webinar on 8 October 3-4PM BST, hosted by DDW and sponsored by Benchling, you will learn about the challenges and advancements driving drug development for cell and gene therapies.
You will hear from Erik Wiklund, CEO of Circio, Ali Pashazadeh, CEO of Treehill Partners, and Gerard Caelles, CBO at Splice Bio.
Erik Wiklund will discuss how circular RNA is crucial to the development of next-generation cell and gene therapy products.
Ali Pashazadeh will explore current barriers and perceptions to the development of cell and gene therapies, examining aspects such as investment and attitudes towards scaling up therapies to treat diseases such as cancer.
Gerard Caelles will discuss the future of CGT drug discovery through the company’s protein splicing platform, designed to tackle diseases that have remained elusive to conventional genetic therapies.
What you will learn:
- Where are the global opportunities created by advanced therapies in drug discovery?
- How sustainable is growth in this area and what should the research sector be focussing on for future success?
- What are the challenges this sector faces, such as skills shortages, or early phase clinical study?
- What are the key trends for this sector?
A Q&A session with the speakers follows the presentations.
